In Week 1 of the Mans International SMAF Sprint 2026, I revisited Insilico Medicine to stress-test the AI-drug premium. The conclusion was clear: the premium is no longer given for technical ambition; it must be earned through measurable scenario maturity.
This week, the SMAF Compass™ 2.0 moves from AI biotech to space infrastructure, frontier AI, and physical robotics.
The case is SpaceX. Through the SMAF lens, the IPO is a scenario-premium case: where investors are being asked to price several maturity layers at once.
Starlink is the current commercial maturity anchor.
Starship is the future capacity promise.
xAI and Grok are the AI imagination layer — but also the unresolved maturity gap.
This raises a harder question: Can mature infrastructure scenarios carry less mature AI scenarios inside the same valuation premium?
That is where the Scenario Maturity Assessment Framework, or SMAF Compass™, becomes useful.
Deconstructing the SpaceX Bundle via the SMAF Lens
A traditional IPO asks investors to value a business. The SpaceX IPO asks investors to value a system: reusable launch, Starlink, Starship, xAI, and the broader Musk narrative.
Deconstructing the SpaceX Bundle via the SMAF Lens
Starlink is the Anchor
Business Maturity: Starlink is the undisputed commercial anchor of the IPO. It has translated deep-tech capability into high-margin, recurring global revenue. From maritime communication and enterprise backup to national defense resilience, the pain point is urgent, the buyer is clear, and the value-capture path is proven. Without Starlink’s business maturity, the broader IPO valuation would be highly fragile.
Data Maturity: Starlink creates a compounding intelligence loop. More users and traffic generate richer network data, which improves routing, reliability, and performance. Better performance increases adoption, and greater adoption deepens the data advantage.
Starlink is the Anchor
Starship is the Capacity Promise
Narrative Maturity: Starship nails this pillar. It gives the market a canvas for its grandest space-based imagination — lunar missions, orbital data centres, and Mars colonization. It converts staggering technical complexity into a highly memorable story of future capacity optionality.
Starship is the Capacity Promise
However, while its Narrative Maturity is maximum, its short-term Business Maturity remains an unproven future option.
xAI is the Unresolved Layer
Workflow Maturity: This is the core maturity gap in the bundle. xAI and Grok inject a massive “AI imagination premium” into the valuation. Yet, serious enterprise and government users still face immense workflow friction: model differentiation, data trust, and deep operational integration.
xAI is the Unresolved Layer
Right now, a highly mature infrastructure scenario (Starlink) is actively carrying a far less mature workflow scenario (xAI) inside the same valuation story.
The Strategic Takeaway for Founders and VCs
Capability shock is not scenario maturity.
A technology company becomes truly investable only when the surrounding scenario matures enough to absorb the innovation and convert it into durable, compounding value.
When evaluating your own tech stack or investment pipeline this quarter, step away from technical specs and ask the tough SMAF questions:
What is your business maturity anchor? What working scenario is generating the predictable revenue needed to subsidize your future bets?
Is your narrative outpacing your workflow? If your Narrative Maturity is a 10, but your Workflow Maturity is a 2, your valuation premium is dangerously fragile.
In the frontier tech era, technology maturity is merely the baseline for entry. Scenario maturity is where the premium is actually earned.
Scenario Maturity is the Premium
Join the Mans International SMAF Sprint 2026
This assessment is Week 2, Case Study 02 of the Mans International SMAF Sprint 2026.
If you are a tech founder, deep-tech VC, industrial leader, or cross-border strategy decision-maker navigating AI, robotics, space infrastructure, or US-China technology decoupling, do not wait for the market to expose the gap.
Your technology may be strong. Your narrative may be compelling. But if the scenario is not mature enough, adoption, revenue, and valuation will eventually break under pressure.
Let’s identify the strategic gaps before the market corrects them.
Send us a direct message to request the proprietary SMAF Compass™ Briefing.
Insilico Medicine and the AI-Drug Premium: A SMAF Stress Test
I first analyzed Insilico Medicine in my 2023 book, when it became one of the most visible pioneers in AI-driven drug discovery.
By 2025, Insilico’s narrative moved beyond sheer R&D velocity. It had become a test of whether AI could translate biological insight into clinically meaningful, commercially viable assets in longevity and age-related disease — through tools like PreciousGPT and its lead asset, Rentosertib.
In 2026, the story became more complex.
Despite a milestone-based Eli Lilly collaboration worth up to $2.75 billion, including a $115 million upfront payment, Insilico’s public-market narrative remains under pressure after a $352.3 million net loss for 2025 and sharp volatility on the HKEX.
That is why I chose Insilico Medicine as an early case for the Mans International SMAF Sprint 2026.
Mans International SMAF Sprint 2026
For founders, the lesson is clear: In AI commercialization, technology maturity does not always coincide with business maturity, capital-market confidence, governance credibility, or narrative maturity.
This is exactly the kind of mismatch the Scenario Maturity Assessment Framework, or SMAF, is designed to examine.
1. Business and Narrative Maturity: “AI-Discovered Drug” Is No Longer Enough
Insilico’s real breakthrough was not simply using AI to discover drugs. It was translating a broad technology promise into a concrete business scenario.
“Aging” itself is not an FDA indication. To build a credible path to market, companies must convert broad healthspan ambition into specific diseases, measurable endpoints, and regulatory logic that investors, pharma partners, and clinicians can evaluate. Insilico did this by targeting IPF, or idiopathic pulmonary fibrosis.
Through an SMAF lens, this is the strategic move. The company did not stay at the level of “AI can discover drugs.” It selected a disease scenario where the technology could be tested against real-world evidence, regulatory, partnership, and business requirements. This is why Rentosertib matters.
The asset moves the conversation from AI discovery speed to a harder question:
Can an AI-enabled biotech company turn discovery into validated assets, strategic partnerships, and repeatable business value?
Business and Narrative Maturity: “AI-Discovered Drug” Is No Longer Enough
In the early AI wave, “AI-discovered drug” was enough to capture attention. By 2026, it will no longer be enough to sustain the premium.
Markets now want specifics: the target, the indication, the endpoint, the regulatory path, the partner logic, and the platform’s repeatability.
For founders, the lesson is clear: AI novelty may open the door. But only a mature business scenario keeps the door open.
A strong narrative does not exaggerate certainty. It shows how technological possibility becomes clinical evidence, commercial value, and investor confidence.
2. Cross-Border Maturity: Speed ≠ Trust
Insilico is especially important because it sits across different geographies, capital systems, and operating logics.
Its links to Hong Kong and China’s biotech infrastructure give it access to real advantages: engineering talent, biotech clusters, automation capacity, scientific speed, cost-efficient R&D execution, and increasingly sophisticated capital-market infrastructure.
But global commercialization requires another layer.
It requires regulatory confidence, clinical transparency, pharma trust, investor communication, data governance, and geopolitical risk management.
This is where globally operating AI biotech companies with strong Hong Kong, China, or Asia-linked R&D networks face a hidden challenge.
Cross-Border Maturity: Speed ≠ Trust
Speed is not enough.
To win globally, they must translate technology, evidence, governance, and narrative into a form that global stakeholders can trust.
Through an SMAF lens, this is not just an expansion strategy. It is a maturity test.
The ultimate question for cross-border founders is: “Can this company become globally legible, credible, and trusted?”
3. The SMAF Takeaway: A Conditional Premium
Did Insilico Medicine pass the SMAF test? Partially.
Insilico has passed some important parts of the SMAF test:
Its AI drug discovery capability appears strong.
Its story has moved from a broad AI-discovery promise to a more concrete disease pathway through Rentosertib and IPF.
The Eli Lilly collaboration strengthens external validation and commercial credibility.
But it has not yet fully passed the broader scenario maturity test.
The remaining question is not whether the technology is impressive.
It is whether the surrounding scenario is mature enough to support repeatable clinical progress, durable commercial value, capital-market confidence, and globally credible governance.
The SMAF Takeaway: A Conditional Premium
That is why the AI-drug premium is not dead. It is being repriced.
Markets will no longer reward AI capability alone. The premium must now be earned through clinical progress, pharma validation, financial discipline, and globally credible governance.
For cross-border biotechs, the real bridge is not just market access. It is the ability to translate speed into trust, science into evidence, and platform ambition into globally legible value.
This is the core question behind the Mans International SMAF Sprint 2026:
If the technology works, is the surrounding scenario mature enough to turn it into adoption, revenue, and durable strategic value?
This is the exact diagnostic we run at the Mans International SMAF Sprint 2026.
At Mans International, we use the Scenario Maturity Assessment Framework (SMAF) to help founders, investors, and strategic leaders diagnose one critical question: If the technology works, is the surrounding scenario mature enough to convert it into adoption, revenue, and durable strategic value?
Most AI health startups ask the wrong question: “What can our technology do?”
Formation Bio asked something far more valuable: “Where is value already trapped — and who has the budget to unlock it?”
That single shift explains why Formation Bio has become one of the most closely watched AI-native drug development companies. The company has reportedly raised about $615 million, reached a valuation of around $1.8 billion, and attracted investors including Sam Altman, Sequoia Capital, and Andreessen Horowitz.
But the real lesson is not that Formation Bio “uses AI.” The real lesson is that Formation Bio chose a mature commercial scenario before scaling the technology. That is what most AI health startups miss.
The Real Bottleneck Was Never Drug Discovery
For years, the dominant AI drug development story has been about discovery:
Find new targets
Generate new molecules
Predict biological behaviour faster than humans
But Formation Bio’s founder and CEO, Ben Liu, saw a different bottleneck.
“Pharma does not lack promising molecules. It lacks a faster, cheaper, more reliable way to move drugs through clinical development.”
Clinical trials are slow, expensive, operationally complex, and filled with execution risk. TIME recently reported that Formation Bio is focused on accelerating administrative and analytical tasks related to trials. Formation Bio:
Buys or in-licenses “stalled” assets — drugs already discovered but shelved by big pharma due to budget cuts, strategic shifts, or portfolio pruning
Uses proprietary AI to “stress-test” and accelerate trials — optimizing patient recruitment, site selection, and protocol design
De-risks and out-licenses — creating value through speed, not novelty
That distinction matters. Formation Bio is not trying to replace pharma’s entire R&D system. It is attacking a painful, expensive bottleneck in a system already facing budget constraints, urgency, and strategic pressure.
That is Scenario Maturity Thinking.
What Is Scenario Maturity?
Scenario Maturity is the difference between a technology that looks impressive and a business that can actually convert.
A mature scenario has three pillars:
The Scenario Maturity Compass
1. Business Maturity
Who actually buys?
Who owns the budget?
Why would they act now?
2. Workflow Maturity
Can the solution fit into real-world operations?
Or does it require customers to change behaviour, rebuild infrastructure, and take on new risk?
3. Data Maturity
Does usage create better data?
Does better data improve the system?
Does that improvement compound into a defensible advantage?
When these three pillars align, revenue has a pathway. When one breaks, even excellent technology can stall.
This is why I often tell founders: technology does not generate revenue on its own. Scenario maturity creates the conditions for revenue.
Clear Buyer Convergence: Who Actually Pays?
Many AI health startups fail because they build for users rather than buyers.
They build for clinicians, patients, researchers, or health platforms — but cannot answer the most important commercial question: Who signs the purchase order?
Formation Bio identified their buyer early: Pharma business development & clinical operations teams at companies like Sanofi and Eli Lilly.
Have multi-billion dollar R&D budgets
Face intense pressure to improve time-to-market
Already understand the value of de-risked late-stage assets
This buyer convergence creates:
Shorter sales cycles (no market education needed)
Higher contract values (ROI is quantifiable: months saved = millions earned)
Strategic partnership opportunities (not just vendor relationships)
Workflow Maturity: AI Embedded Into the Real Job
One of the biggest mistakes AI startups make is selling AI as a product.
Formation Bio avoids this trap. In partnership with OpenAI and Sanofi, Formation Bio launched Muse, an AI tool designed to analyze scientific literature and generate tailored patient recruitment materials, cutting recruitment timelines from months to minutes.
Muse is embedded into Formation Bio’s trial acceleration workflow. Customers don’t buy “AI correlation.” They buy:
Lower trial costs → higher margin on out-licensed assets
Reduced execution risk → more predictable ROI
This is the key lesson for founders: AI becomes valuable when it disappears into the workflow and improves the business outcome.
If your customer has to stop, learn, reconfigure, and take on extra operational risk to use your product, your scenario maturity is low.
Data Maturity: The Closed Loop Most Startups Never Build
Most AI health startups face a “cold start” problem:
Data is fragmented across EHRs, wearables, and trials
Feedback loops are weak or non-existent
Model improvements don’t compound into business value
Formation Bio engineered a closed data loop:
Clinical trial execution → Real-world trial data → AI model iteration → Faster, cheaper next trial → Higher asset valuation
This creates:
Compounding advantage: Each trial makes the platform smarter
Defensible moat: Proprietary trial execution data can’t be scraped or replicated
Investor confidence: Clear path to margin expansion as the platform scales
This isn’t just a biotech story. It’s a scenario selection story — and it applies to every complex market.
The Kintsugi Contrast
This is why the contrast between Kintsugi and Formation Bio is so important.
Kintsugi had impressive technology: AI-based voice biomarkers for detecting depression. It had a compelling mission, clinical signal, and strong investor interest.
But the commercial scenario was much harder.
Who pays?
Hospitals?
Employers?
Health plans?
Digital health platforms?
Clinics?
Each buyer had different incentives, budgets, workflows, and risk concerns.
That created a scenario maturity gap.
Formation Bio, by contrast, chose a clearer buyer, a known pain point, a measurable ROI, and a workflow where AI could improve execution without requiring the whole market to change first.
That is the difference between promising technology and investable momentum.
Why This Matters for Every Tech Founder
Formation Bio’s lesson is universal: Success isn’t about better tech — it’s about smarter scenario selection.
Before you scale, ask:
Budget vs. Buzz: Is there an existing procurement line for your solution — or just interest?
Fit vs. Friction: Does your product plug into existing workflows, or require behaviour change?
Leverage vs. Labour: Does every customer make your system stronger — or add custom work?
Causation vs. Correlation: Can your buyer measure ROI in cost savings, revenue gains, or risk reduction?
If your technology is strong but revenue is slow, the problem may not be the product.
It may be your scenario maturity.
At Mans International, this is exactly what we help founders diagnose: where your product is getting stuck, why the market is not converting, and what must change before investors, customers, or strategic partners are ready to move.
Our expertise lies in Scenario Maturity Thinking — helping founders assess whether their technology is entering a market where the buyer, budget, urgency, data, and value-capture logic are mature enough to support real commercialization.
Because in today’s market, the winners are not always the companies with the most impressive technology.
They are the companies that know exactly where value is trapped, who has the incentive to unlock it, and how to convert that insight into revenue, partnership, and scale.
